Precision Medicine Pioneers
Towards a world where NGS-based companion diagnostics are available, in house, for every new cancer therapy and every patient
sponsored by Thermo Fisher Scientific
As Thermo Fisher Scientific’s Oncomine Dx in-house NGS solutions go from strength to strength, so strengthens their vision of worldwide availability of ultra-rapid NGS-sequencing-based solutions.
In this interview with The Pathologist, Luca Quagliata reflects on Thermo Fisher Scientific’s history in precision medicine, the priorities driving their current strategy, and future predictions for the field.
Vice-President, Medical Affairs, Clinical Next-Generation Sequencing Division, Genetic Sciences Group, Thermo Fisher Scientific